LIDDS AB European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical results. The study met both primary and secondary endpoints by confirming efficacy and safety with Liproca Depot given as intraprostatic injection in low- and intermediate risk prostate cancer patients. “We are pleased that this manuscript is accepted in a highly recognized scientific paper and the results further validates NanoZolid® as being an innovative technology platform,” said Monica Wallter, CEO of LIDDS.